DR. JUNAID AHMED BAKHTIYAR ZAMAN MA, BMBCH, MRCP, PHD
Prescription History 1588198303
Internal Medicine - Clinical Cardiac Electrophysiology in Los Angeles, CA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JUNAID AHMED BAKHTIYAR ZAMAN MA, BMBCH, MRCP, PHD, an active Clinical Cardiac Electrophysiology specialist practicing in Los Angeles, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 180 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 78 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other CA PrescribersVs. CA Avg |
|---|---|---|---|
| EliquisApixaban | 78 | $1,199.24 | ≈ Typical |
About Eliquis: Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Show more ▾ With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood. In 2023, this provider wrote 78 Medicare prescriptions for Eliquis, about the same volume as the typical California prescriber of this medication (68). Medicare paid an average of $1,199.24 per fill, versus $848.49 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 166 30-Day Fills standardized to 30-day supplies 4,980 Days of Medication total across all patients in 2023 | |||
| Metoprolol Succinate | 42 | $23.29 | ▼ Less than typical |
About Metoprolol Succinate: This medication is a beta-blocker used to treat chest pain (angina), heart failure, and high blood pressure. Show more ▾ Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This drug works by blocking the action of certain natural chemicals in your body (such as epinephrine) that affect the heart and blood vessels. This lowers heart rate, blood pressure, and strain on the heart. A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. In 2023, this provider wrote 42 Medicare prescriptions for Metoprolol Succinate, about half the volume of the typical California prescriber of this medication (82). Medicare paid an average of $23.29 per fill, versus $20.10 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 113 30-Day Fills standardized to 30-day supplies 3,390 Days of Medication total across all patients in 2023 | |||
| Flecainide Acetate | 34 | $51.00▼ below CA avg | ≈ Typical |
About Flecainide Acetate: This medication is used to treat certain types of serious (possibly fatal) irregular heartbeat (such as sustained ventricular tachycardia and paroxysmal supraventricular tachycardia). Show more ▾ It is used to restore normal heart rhythm and maintain a regular, steady heartbeat. It is also used to prevent certain types of irregular heartbeat from returning (such as atrial fibrillation). Flecainide is known as an anti-arrhythmic drug. It works by blocking certain electrical signals in the heart that can cause an irregular heartbeat. Treating an irregular heartbeat can decrease the risk for blood clots, and this effect can reduce your risk of heart attack or stroke. Older adults should discuss the risks and benefits of this medication with their doctor or pharmacist, as well as other effective and possibly safer treatments. A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS. In 2023, this provider wrote 34 Medicare prescriptions for Flecainide Acetate, about 77% of the volume of the typical California prescriber of this medication (44). Medicare paid an average of $51.00 per fill, versus $65.91 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 88.2 30-Day Fills standardized to 30-day supplies 2,608 Days of Medication total across all patients in 2023 | |||
| XareltoRivaroxaban | 26 | $838.49▼ below CA avg | ▼ Less than typical |
About Xarelto: Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. Show more ▾ It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood. A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME. In 2023, this provider wrote 26 Medicare prescriptions for Xarelto, about half the volume of the typical California prescriber of this medication (44). Medicare paid an average of $838.49 per fill, versus $907.01 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 36 30-Day Fills standardized to 30-day supplies 1,080 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for DR. JUNAID AHMED BAKHTIYAR ZAMAN MA, BMBCH, MRCP, PHD is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Clinical Cardiac Electrophysiology prescribing approach at this Los Angeles, CA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among CA prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
